Company Overview

Medicamen Organics Limited was originally incorporated on March 15, 1995, as 'Panchdeep Pharmaceuticals Limited', a Public Limited Company. Subsequently, the company's name was changed to 'Medicamen Organics Limited', with a fresh Certificate of Incorporation issued on November 14, 1995. The company operates under the NSE symbol MEDIORG and trades on the NSE SME platform, having made its market debut following a successful IPO in June 2024.

Medicamen Organics is engaged in the development, manufacturing, and distribution of a broad range of pharmaceutical dosages, including generic formulations in the form of Tablets, Capsules, Oral Liquids, Ointments, Gels, Syrups, Suspensions, and Dry Powders. These products are supplied to both Government (State and Central) and Private Institutions, primarily as a contract manufacturer or third-party manufacturer. The Company also markets its products to private pharma companies in domestic and international markets, either through third-party distributors or on a loan license basis.

Business Operations and Market Presence

MOL specializes in the manufacturing and distribution of tablets, capsules, syrups, and ointments. It offers B2B contract and third-party manufacturing services for pharmaceutical companies in India and globally. Its portfolio includes generic and branded formulations, catering to government sectors, private institutions, and prominent pharma firms. Products are marketed via third-party distributors and loan licensing agreements.

The company has established a significant international footprint, with operations spanning across multiple continents. Its business is diversified in terms of geographies and therapeutic areas within the pharmaceutical industry. Geographically, it has a presence in India and holds registrations for manufacturing products approved in international markets such as Congo, Benin, Togo, Senegal, Burkina Faso, Philippines, Myanmar, Mozambique, Burundi, Kyrgyzstan, and Kenya. The company's product portfolio comprises 84 distinct products.

Financial Performance

Medicamen Organics has demonstrated robust financial growth in recent periods. The company reported impressive financial results for FY25, showcasing strong performance across key metrics.

FY25 Performance Highlights:

- Revenue from Operations: ₹3,818.77 lakhs (representing a 51% year-on-year growth).

- Net Worth: ₹3,048.07 lakhs (nearly doubled, indicating solid financial health and operational efficiency).

- Profit After Tax (PAT) Growth: Witnessed a remarkable 101% growth in the second half of the fiscal year (H2 FY25).

H1 FY25 Performance Highlights:

- Total Revenue: ₹1,685.66 Lakhs (YoY growth of 48.91%).

- EBITDA: ₹277.44 Lakhs.

- Net Profit: ₹151.07 Lakhs (YoY growth of 10.88%).

Market Position and Valuation

Medicamen Organics Ltd (MEDIORG) had a market capitalization of ₹56.98 Cr as of 25th June 2025. The stock has experienced significant volatility since its listing.

- 52-Week High: ₹159.40

- 52-Week Low: ₹19.60

- P/E Ratio: 14.07

Shares of Medicamen Organics were quoting at ₹144.70 on the NSE, representing a premium of 325.59% compared to its issue price of ₹34 at the time of its debut in June 2024, indicating strong initial investor confidence.

Corporate Structure and Shareholding

As of the last reported quarter for Medicamen Organics Ltd:

- Promoter Holding: 59.7% (with Mr. Bal Kishan Gupta being the promoter).

- FII Holding: 0.1%

- DII Holding: 3.8%

- Public Holding: 36.4%

The promoter holding pattern suggests strong management control while maintaining adequate public participation.

Recent Strategic Developments

The company has embarked on several strategic initiatives to drive future growth and diversification.

- Cosmetics and Personal Care Entry: In June 2025, Medicamen announced its formal entry into the cosmetics and personal care industry through its subsidiary, Grande Etiole Pharmaceuticals Limited. This move is a significant milestone for its long-term growth and diversification strategy.

- Nepal Facility Investment: The company is investing INR 9 Cr in a new facility in Nepal.

- Mauritius Operations & Product Launch: Medicamen Organics has launched operations in Mauritius, introducing 22 cosmetic products in July 2024, targeting ₹3 Cr in sales within the first year. This expansion underscores the company's commitment to geographical diversification and entering new product categories beyond traditional pharmaceuticals.

- Growth Targets: The company targets a 60% CAGR.

Stock Exchange Information

Medicamen Organics Ltd trades on the NSE under the symbol MEDIORG and has the ISIN code INE0PE401018.

- Listing Date: The shares were listed on the NSE SME on June 28, 2024.

- IPO Details: The Medicamen Organics IPO bidding period was from June 21, 2024, to June 25, 2024. The allotment was finalized on Wednesday, June 26, 2024.

Medicamen Organics' transition from a traditional pharmaceutical manufacturer to a diversified healthcare and cosmetics player, combined with its strong financial performance and expanding international presence, positions it as an emerging entity in the SME segment of the Indian stock market.